Fundraising FoxNewomics
Berkeley, US · Delaware corporation · 3 known investors
Find your way into Newomics
Sign up to see every warm intro you have to Newomics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Newomics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Newomics develops the UniESI system, a multiomics front-end platform using its M3 emitter and MEA chip "multispray" technologies for microflow and nanoflow LC-MS. The system serves as a dual nano/micro ion source for mass spectrometers, targeting applications in native MS, proteomics, metabolomics, and single-cell omics.
Founders & leadership
Board
Investors · 3
How we know: the VCSheet dataset · Not right? Tell us
How we know: funding news · Not right? Tell us
How we know: funding news · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$3.9M disclosed across 1 round · 2020
▶$3.9MraisedOct 2020 · 10 investors · BiotechnologyRule 506(b)
- Pan MaoDirector
- Patrick ScannonDirector
- Ted HouDirector
- Daojing WangExecutive Officer, Director
- Offering amount
- $7.9M
- Amount sold
- $3.9M
- First sale
- Oct 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 3
Companies working in the same space as Newomics.
Non-dilutive funding · 13 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2022 | $1.7M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2019 | $3M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2018 | $1.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2016 | $1.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2016 | $1.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2015 | $1.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2014 | $700K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2014 | $683.2K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2014 | $600K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2014 | $225K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2013 | $300K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2013 | $225K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2012 | $250K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Newomics do?
- Newomics develops the UniESI system, a multiomics front-end platform using its M3 emitter and MEA chip "multispray" technologies for microflow and nanoflow LC-MS. The system serves as a dual nano/micro ion source for mass spectrometers, targeting applications in native MS, proteomics, metabolomics, and single-cell omics.
- Who founded Newomics?
- Newomics was founded by Pan Mao, Daojing Wang.
- Who are Newomics's investors?
- Newomics's investors include Berkeley Catalyst, LDV Partners, MSA Capital.
- How much funding has Newomics raised?
- Newomics has disclosed $3.9M raised across 1 round.
- Where is Newomics headquartered?
- Newomics is headquartered in Berkeley, US.